By | Rachel Brooks
Staff | Telegraph Local
Above, CBC The National broadcast captures drug production.
A medical group has endorsed anti-malarial drug treatment for coronavirus patients, the International Business Times reports. The drugs have been issued to critical patients, despite the fact that antimalarial drugs are still in the experimental phase of treating COVID-19 specifically. The American Thoracic Society has nevertheless promoted anti-malarial drugs for COVID-19 with confidence.
Some Swedish hospitals have stopped using chloroquine to treat COVID-19 after reports of severe side effects
The Thoracic Society released this statement regarding the experimental use of the drug,
“To prescribe hydroxychloroquine (or chloroquine) to hospitalized patients with COVID-19 pneumonia if all of the following apply: a) shared decision-making is possible, b) data can be collected for interim comparisons of patients who received hydroxychloroquine (or chloroquine) versus those who did not, c) the illness is sufficiently severe to warrant investigational therapy, and d) the drug is not in short supply,” as quoted by the International Business Times.
The Thoracic Society also stated that their guidelines came from the guidelines of the COVID-19 task force.
The Thoracic Society also quoted Dr. Kevin Wilson, the chief of Guidelines and Documents at the American Thoracic Society. As follows,
“We believe that in urgent situations like a pandemic, we can learn while treating by collecting real-world data. There are in vitro studies that suggest that hydroxychloroquine and chloroquine have activity against SARS-CoV-2019, the virus that causes COVID-19.”
The CDC has listed hydroxychloroquine as one of the therapeutic options for COVID-19. CDC describes the drugs as oral prescription drugs. They have been used for the treatment of malaria and inflammatory conditions. One of these conditions is called chemoprophylaxis. A study from China reported that chloroquine treatment of COVID-19 patients had clinical and virologic benefits versus a comparison group, citing the CDC.
The CDC still reports that the drug is under clinical trial and is under current investigation to see the effectiveness, dosage, and duration one should use hydroxychloroquine or anti-malarials. To see more facts regarding the hydroxychloroquine trials, visit Clinical Trials.gov. Clinical Trials.gov is part of the National Library of Medicine.
On March 25, the CDC also reported new information on the FDA approved chloroquine and hydroxychloroquine drugs. Trials are still needed because exceeding the proper dosage of either drug could lead to death or serious side effects.
The clinical trial of hydroxychloroquine has been the subject of intense politicization. The Hill reported that President Trump had pushed the U.S. public health officials to test the anti-malarial drug. The White House denied any pressure campaign. The White House statement reads as follows,
“The President’s top priority is the health and safety of the American people which is why he has brought together the federal government and private sector, including doctors, scientists, and medical researchers, for an unprecedented collaboration to expedite vaccine development,”as quoted by The Hill.
The CDC likewise reported that they had been requested by the task force to review the potential usability of the anti-malarial drug.
The FDA likewise reported that the emergency use of antimalarials for the COVID-19 was in the best interest of patients. The FDA released a statement that reads as follows as quoted by The Hill,
“It was determined, based on the scientific evidence available, that it is reasonable to believe that the specific drugs may be effective in treating COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus outweigh the known and potential risks,”
The Telegraph Local earlier reported that some hospitals, such as those in Sweden, have discontinued the use of anti-malarial drugs after severe side effects. The general effectiveness or general adverse side effects of using these drugs remains to be seen. This is a developing story.